Research Institute At Nationwide Children's Hospital

Research Institute At Nationwide Children's Hospital, a tax-exempt nonprofit research subsidiary of Nationwide Children's Hospital in Columbus, Ohio, serves as a prime recipient of federal grants and, to a lesser extent, a prime contractor, delivering biomedical and clinical research across pediatric oncology, infectious disease, cardiology, neurology, and rare genetic disorders. The institute competes predominantly in full-and-open federal funding rather than set-aside vehicles; it receives no SBA certifications.

The institute's research footprint spans NIH-funded basic science, translational studies, and clinical trial coordination. Recent prime grant work includes a $3.218 million FDA award (CFDA 93.103) supporting a Phase II molecularly-guided umbrella trial for high-grade glioma and diffuse intrinsic pontine glioma in pediatric and young-adult patients, with clinical protocol development, patient enrollment, and biomarker evaluation running through August 2029. The National Heart, Lung, and Blood Institute awarded $3.147 million for research on surgical strategies to improve outcomes after Fontan surgery in children with single-ventricle disease, addressing Fontan-associated liver disease through investigation of somatic overgrowth and compliance mismatch in biomaterials. The National Cancer Institute funded $608,558 to genetically and metabolically define high-risk neuroblastoma, exploring gamma-aminobutyric acid metabolism as a characteristic metabolite that enhances tumor proliferation while suppressing CD8 T-cell function. Additional representative work includes NIH awards on gene therapy (adeno-associated virus EIF2B5 replacement for vanishing white matter disease, $859,821 from NINDS), pediatric clinical research (spinal muscular atrophy, Duchenne muscular dystrophy), and population health science (ultrasound utilization in rural pediatric care disparities, $446,046 from NIMHD).

Customer concentration centers heavily on the National Institutes of Health. The National Cancer Institute leads by award count (139 awards) and dollars ($144.3 million combined potential value), representing the dominant funder across the portfolio. The National Heart, Lung, and Blood Institute (110 awards), National Institute of Allergy and Infectious Diseases (85 awards), and National Institute of Diabetes and Digestive and Kidney Diseases (69 awards) comprise secondary customer clusters. The Health Resources and Services Administration (HRSA) is the second-largest customer by dollar value ($15.9 million across 10 awards), driven by a $10 million Indefinite Delivery Contract supporting the Advisory Committee on Heritable Disorders in Newborns and Children through evidence-based reviews, decision-aid development, and technical advisory services. These top five agencies and NIH offices account for 50% of recent award volume; the concentration reflects the institute's positioning as a NIH-heavy research center with minimal federal contracting exposure outside health and human services.

Vehicle positioning shows limited IDV participation compared to research grant dominance. The institute holds a seat on NCI Cancer Genome Atlas Program Tissue Purchase arrangements and operates under HRSA's ten-million-dollar IDC for newborn screening advisory services. An HHSN261201700015I IDC carries 9 task orders valued at $36.4 million, and IDC 75R60221D00001 includes 9 task orders at $5.9 million. No GWAC or government-wide multiple-award schedule participation appears in the recent portfolio, reflecting the institute's grant-centric positioning rather than full-and-open commercial services competition.

Activity has grown substantially over the past five years—from 98 awards in 2023 to a peak of 172 in 2024—before moderating to 115 in 2025 and 92 in 2026. This trajectory reflects both increased grant award volume and potential program consolidation or completion cycles. One hundred four awards (combined potential value $12 million) face ultimate completion within the next twenty-four months, representing significant recompete exposure, particularly in multi-year NIH grant cycles where principal investigator continuity and prior publication track record anchor renewal competitiveness.

Service Contract Inventory data captures only a subset of the institute's federal engagement, excluding grants and non-service work. SCI-reported invoicing totaled $9.4 million across FY2022–FY2025 (prime contracts only), with peak activity in FY2022 at $3.1 million and modest fluctuation thereafter ($1.7 million in FY2023, $2.1 million in FY2024, $2.5 million in FY2025). FTE trajectory from SCI-reportable contracts shows volatility: FY2022 reported 540 FTEs (a data artifact from contract-level aggregation), then collapsed to 9.9 FTEs in FY2023 before rising to 95.8 FTEs in FY2024 and moderating to 17.7 FTEs in FY2025. Hourly rate posture on SCI-reportable prime contracts ranged from $0/hr (likely non-labor or cost-sharing entries) to a 90th percentile of $627/hr, with a median of $60.12/hr, reflecting a mix of research support labor (lower-paid technicians and coordinators) and highly specialized scientific roles. Across SCI-reportable prime contracts, subcontractors accounted for an average of 11% of total contractor hours, with 17 named subcontractors appearing across the prime SCI portfolio, indicating the institute builds most of its delivery capacity in-house and uses subs for specialized or adjunct services.

The institute functions predominantly as a prime grant recipient (60% of recent awards) and maintains a smaller subcontractor footprint (40% of awards), appearing as a named sub on multi-institutional clinical trials and research consortia led by academic medical centers and NIH intramural programs. Named prime primes receiving the institute as a sub include the University of Pittsburgh (MATIC-2 trauma resuscitation trial), University of Alabama at Birmingham (IGF-OT-IGF viral infection research), and Duke University (PEP-CMV immunotherapy trial for pediatric medulloblastoma), signaling integration into national pediatric research networks rather than defense or commercial contracting ecosystems. The institute operates as Abigail Wexner Research Institute, a subsidiary brand emphasizing gene therapy (Center for Gene Therapy, FDA-approved therapies for spinal muscular atrophy and Duchenne muscular dystrophy), pediatric cancer research (Center for Childhood Cancer Research), and clinical research infrastructure anchored to Nationwide Children's Hospital's academic-clinical partnership with The Ohio State University College of Medicine.